Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

It's time.

Brian P Smith1

  • 1Eli Lilly and Company, Lilly Corporate Center, Drop Code 2233, Indianapolis, IN 46285, USA. b.smith@lilly.com

The AAPS Journal
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Statistical inference enhances drug development decisions by leveraging probability and model results. Integrating statistical and pharmacometric efforts maximizes clinical research potential, avoiding common pitfalls.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.

Cancer discovery·2026
Same author

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.

Science (New York, N.Y.)·2025
Same author

Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C.

Cancer discovery·2024
Same author

High-Throughput Cell-Based Screening of Small Molecule KRAS Signaling Inhibitors Using a Homogeneous Time-Resolved Fluorescence (HTRF) Assay.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

FLAG-KRAS4B as a Model System for KRAS4B Proteoform and PTM Evaluation by Mass Spectrometry.

Methods in molecular biology (Clifton, N.J.)·2024
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Area of Science:

  • Pharmacometrics
  • Statistical Inference
  • Drug Development

Background:

  • Statistical inference uses probability and model results for decision-making.
  • Drug development relies on informed decisions regarding drug efficacy and safety.
  • Pharmacometric modeling is a key tool in drug development.

Purpose of the Study:

  • To explain the utility and pitfalls of statistical inference in drug development.
  • To examine barriers to integrating statistical inference in pharmacometric modeling.
  • To demonstrate the advantages of mechanistic models in statistical inference.

Main Methods:

  • Commentary on the application of statistical inference.
  • Examination of integration challenges in pharmacometric modeling.

Related Experiment Videos

  • Illustrative example of mechanistic models for inference.

    • Main Results:

    • Statistical inference offers significant advantages in decision-making within drug development.
    • Mechanistic models provide superior inferential capabilities.
    • Current integration of statistical inference in pharmacometrics is suboptimal.

    Conclusions:

    • Enhanced integration of statistical inference and pharmacometrics is crucial.
    • Collaboration between statisticians and pharmacometricians can optimize clinical research.
    • Addressing pitfalls in statistical inference improves drug development outcomes.